[{"orgOrder":0,"company":"Lindus Health","sponsor":"Acinonyx Bio","pharmaFlowCategory":"D","therapeuticArea":"Dermatology","country":"","productType":"Plant Extract\/Herbal","year":"2024","type":"Collaboration","leadProduct":"Alpha-Cyclodextrin","moa":"Undisclosed","graph1":"Dermatology","graph2":"Preclinical","graph3":"Lindus Health","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Dermatology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Lindus Health \/ Acinonyx Bio","highestDevelopmentStatusID":"4","companyTruncated":"Lindus Health \/ Acinonyx Bio"}]

Find Clinical Drug Pipeline Developments & Deals by Lindus Health

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          SCI Medicinal Chemistry
                          Not Confirmed
                          SCI Medicinal Chemistry
                          Not Confirmed

                          Details : The collaboration aims to conduct the clinical development of ACX, which is evaluating their topical cream's ability to treat patients with moderate to severe inflammatory acne.

                          Product Name : ACX

                          Product Type : Plant Extract/Herbal

                          Upfront Cash : Undisclosed

                          May 16, 2024

                          Lead Product(s) : Alpha-Cyclodextrin

                          Therapeutic Area : Dermatology

                          Highest Development Status : Preclinical

                          Sponsor : Acinonyx Bio

                          Deal Size : Undisclosed

                          Deal Type : Collaboration

                          blank